Teen Boys Taking Cancer Drug to Grow Taller
Teen Boys Taking Cancer Drug to Grow Taller
Teen Boys Taking Cancer Drug to Grow Taller
Key points
اہم نکات
मुख्य बातें
- Teenage boys as young as 15 are taking erdafitinib, a powerful cancer drug, in a dangerous online trend called “heightmaxxing” to try to grow taller, doctors warn.
- The drug, sold as Balversa and approved only for certain advanced bladder cancers in adults, is being bought on black markets after a small 2024 study noted unexpected growth in two children treated for brain tumors.
- Doctors say the growth spurts are not healthy bone growth and warn of permanent vision damage, bone fractures, growth plate damage and other serious side effects.
- Teenage boys as young as 15 are taking erdafitinib, a powerful cancer drug, in a dangerous online trend called “heightmaxxing” to try to grow taller, doctors warn.
- The drug, sold as Balversa and approved only for certain advanced bladder cancers in adults, is being bought on black markets after a small 2024 study noted unexpected growth in two children treated for brain tumors.
- Doctors say the growth spurts are not healthy bone growth and warn of permanent vision damage, bone fractures, growth plate damage and other serious side effects.
- Teenage boys as young as 15 are taking erdafitinib, a powerful cancer drug, in a dangerous online trend called “heightmaxxing” to try to grow taller, doctors warn.
- The drug, sold as Balversa and approved only for certain advanced bladder cancers in adults, is being bought on black markets after a small 2024 study noted unexpected growth in two children treated for brain tumors.
- Doctors say the growth spurts are not healthy bone growth and warn of permanent vision damage, bone fractures, growth plate damage and other serious side effects.
Teenage boys as young as 15 are taking erdafitinib, a powerful cancer drug, in a dangerous online trend called “heightmaxxing” to try to grow taller, doctors warn. The drug, sold as Balversa and approved only for certain advanced bladder cancers in adults, is being bought on black markets after a small 2024 study noted unexpected growth in two children treated for brain tumors. Doctors say the growth spurts are not healthy bone growth and warn of permanent vision damage, bone fractures, growth plate damage and other serious side effects. Johnson & Johnson, which makes the drug, says it has never been approved to increase height and its safety in children and teenagers has never been established.
Teenage boys as young as 15 are taking erdafitinib, a powerful cancer drug, in a dangerous online trend called “heightmaxxing” to try to grow taller, doctors warn. The drug, sold as Balversa and approved only for certain advanced bladder cancers in adults, is being bought on black markets after a small 2024 study noted unexpected growth in two children treated for brain tumors. Doctors say the growth spurts are not healthy bone growth and warn of permanent vision damage, bone fractures, growth plate damage and other serious side effects. Johnson & Johnson, which makes the drug, says it has never been approved to increase height and its safety in children and teenagers has never been established.
Teenage boys as young as 15 are taking erdafitinib, a powerful cancer drug, in a dangerous online trend called “heightmaxxing” to try to grow taller, doctors warn. The drug, sold as Balversa and approved only for certain advanced bladder cancers in adults, is being bought on black markets after a small 2024 study noted unexpected growth in two children treated for brain tumors. Doctors say the growth spurts are not healthy bone growth and warn of permanent vision damage, bone fractures, growth plate damage and other serious side effects. Johnson & Johnson, which makes the drug, says it has never been approved to increase height and its safety in children and teenagers has never been established.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।